ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 935,31
1,03%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) Actualités

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
De:
Trier par:
 Showing the most relevant articles for your search:LSE:HCM
DateHeureSourceTitreSymboleSociété
28/06/202413h35RNS Non-RegulatoryHutchmed (China) Limited Overseas Regulatory Announcement: Form F-3 FilingLSE:HCMHutchmed (china) Limited
28/06/202410h30RNS Regulatory NewsHutchmed (China) Limited Total Voting RightsLSE:HCMHutchmed (china) Limited
28/06/202410h30RNS Regulatory NewsHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:HCMHutchmed (china) Limited
26/06/202410h30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2024 HY Financial ResultsLSE:HCMHutchmed (china) Limited
24/06/202411h30RNS Non-RegulatoryHutchmed (China) Limited Save the Date: HUTCHMED to Present R&D UpdatesLSE:HCMHutchmed (china) Limited
24/06/202411h00Alliance NewsAlliance NewsIN BRIEF: Hutchmed China notes Takeda obtains EU approval for FruzaqlaLSE:HCMHutchmed (china) Limited
24/06/202408h00RNS Regulatory NewsHutchmed (China) Limited European Commission Approval for FRUZAQLALSE:HCMHutchmed (china) Limited
17/06/202411h32Alliance NewsAlliance NewsHutchmed celebrates "promising" results for sovleplenib in ChinaLSE:HCMHutchmed (china) Limited
17/06/202408h00RNS Non-RegulatoryHutchmed (China) Limited Lancet Publish Phase III ESLIM-01 ResultsLSE:HCMHutchmed (china) Limited
07/06/202419h13Alliance NewsAlliance NewsIN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506LSE:HCMHutchmed (china) Limited
07/06/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase I Trial of HMPL-506LSE:HCMHutchmed (china) Limited
03/06/202408h00RNS Non-RegulatoryHutchmed (China) Limited Nature Medicine Publish Phase III FRUTIGA ResultsLSE:HCMHutchmed (china) Limited
24/05/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Presentations at 2024 ASCO Annual MeetingLSE:HCMHutchmed (china) Limited
17/05/202418h58Alliance NewsAlliance NewsIN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan EldarLSE:HCMHutchmed (china) Limited
17/05/202416h00RNS Regulatory NewsHutchmed (China) Limited Retirement of Chairman and new Chairman appointedLSE:HCMHutchmed (china) Limited
17/05/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Data to be Presented at EHA2024 CongressLSE:HCMHutchmed (china) Limited
14/05/202415h33Alliance NewsAlliance NewsHutchmed announces trials of HMPL-306 and Surufatinib cancer therapiesLSE:HCMHutchmed (china) Limited
14/05/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase II/III Trial with HengruiLSE:HCMHutchmed (china) Limited
14/05/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Registrational Phase III TrialLSE:HCMHutchmed (china) Limited
10/05/202414h00RNS Regulatory NewsHutchmed (China) Limited Result of AGMLSE:HCMHutchmed (china) Limited
08/05/202410h30RNS Regulatory NewsHutchmed (China) Limited Directorate ChangeLSE:HCMHutchmed (china) Limited
26/04/202417h09Alliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
26/04/202414h30RNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
22/04/202410h30RNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
08/04/202410h30RNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
05/04/202410h30RNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
02/04/202411h32Alliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
02/04/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
28/03/202412h08Alliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
28/03/202408h00RNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

Dernières Valeurs Consultées

COIN
SCAMETH
SCAM
BIT
P21779
NLBNPIT21779 20351221 28...
USOTC
MCHIF
Maruichi Steel Tube (PK)
LSE
NTWX
Nettworx
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés